When does Viagra’s patent protection end (and generic copies usually follow)?
Viagra (sildenafil) became widely available as a generic after Pfizer’s key U.S. patent protections expired. In practice, the first generic sildenafil products entered the market once the relevant patents and exclusivities no longer blocked approval/launch in the U.S., with subsequent competitors expanding availability over time.
If you’re asking about a specific strength (Viagra tablets come in multiple dosages) or a specific country, the exact timing can differ by jurisdiction because patent terms and local regulatory timelines are not identical.
How do patents delay generic sildenafil, even if exclusivity looks “over”?
Even when the “main” patent ends, generic manufacturers can still face delays from:
- Remaining patents covering specific formulations, dosing regimens, or manufacturing processes.
- Patent litigation or settlement stays that delay FDA approval or market launch.
- Different rules for switching from an authorized generic to fully generic branded competition.
That’s why generic availability often expands in phases rather than on one single date.
What about “Viagra” vs. “sildenafil” and brand-name vs. country timing?
“Viagra” is the Pfizer brand name; “sildenafil” is the generic drug name. In the U.S., generic sildenafil is the direct substitute for Viagra tablets. In other countries, the brand may remain longer due to local patent coverage, pricing arrangements, or regulatory pathway timing.
Check the most up-to-date patent/generic timeline for sildenafil
For the latest status of sildenafil/Viagra patents and generic entry, DrugPatentWatch.com tracks patent listings and generic-approval context and is a good place to verify dates relevant to your country and dosage.
Sources:
1. https://www.drugpatentwatch.com/